In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

Scientists at Michigan Medicine have made a significant breakthrough in treating nonalcoholic fatty liver disease (NAFLD), a ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better ...

A study from Massachusetts General Hospital has found that growth hormone may help improve liver health in people with ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

Non-alcoholic fatty liver disease (NAFLD) is a condition in which fat builds up in your liver, and there are a number of ...

Nonalcoholic fatty liver disease (NAFLD ... Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

Recent statistics reveal that approximately 63% of UK adults are either overweight or obese, and it's estimated that one in three have early-stage non-alcoholic fatty liver disease (NAFLD).

Here, we argue that metabolic dysfunction-associated steatotic liver disease should be considered a non-communicable disease.